Clinical Sciences Research Division

The Clinical Sciences Division seeks to enhance cancer care through innovative research into cancer genetics, novel therapies and stem cell transplants as well as finding better treatment options across all disease areas.

-This Division is led by Jonathan Licht, MD.

Women's Cancer Program (WC) - View Members

Characterize and define the molecular mechanisms of hormonal signal transduction and cross-talk which contribute to women's cancer progression.

Develop animal model systems to evaluate new agents or approaches for the treatment and prevention of women's cancer.

Initiate clinical studies that will define molecular markers & test new agents for the prevention, early detection, or treatment of women's cancer.

Translational Research in Solid Tumors Program (TRIST) - View Members

Characterize basic molecular mechanisms of cancer development and progression and identify novel targets for therapy.

Develop preclinical animal models to test novel therapeutics to treat solid cancers.

Initiate and conduct clinical studies to test and validate novel approaches and technologies for the detection and treatment of solid cancers.

Hematologic Malignancies (HM) - View Members

Characterize normal hematopoiesis and define the genetic alterations associated with hematologic malignancies.

Identify molecular targets and evaluate the efficacy of novel therapeutic compounds.